Ottawa, Ontario (PRWEB)
December 15, 2015
Spartan Bioscience currently announced that Sean Tomalty has been named Vice President, Manufacturing. Mr. Tomalty will lead a prolongation of Spartan’s DNA evidence inclination and tests.
“Sean is an glorious further to Spartan’s care team,” pronounced Paul Lem, M.D., CEO of Spartan Bioscience. “Sean has low imagination in medical device manufacturing, and he will play a pivotal purpose in a prolongation of Spartan’s DNA inclination and tests.”
Mr. Tomalty joins Spartan with some-more than 30 years of knowledge in operations and prolongation during companies including Abbott Point of Care, JDSU, and Nortel. At Abbott, he was Plant Director of a 500,000 square-foot medical device prolongation trickery that constructed a i-STAT® unstable clinical analyser and 35 million exam cartridges annually.
Mr. Tomalty binds a Bachelor of Mechanical Engineering grade from Carleton University and a Masters of Business Administration grade from Queen’s University. He is a protected Professional Engineer.
For some-more information about careers during Spartan, greatfully revisit http://www.spartanbio.com/about-us/careers/.
About Spartan Bioscience
Spartan Bioscience is a personality in on-demand DNA testing.(1) Spartan is bringing finish sample-to-result DNA contrast systems to medicine. Spartan’s record entirely integrates DNA collection, extraction, and analysis, with an discerning interface that is easy to operate. For a initial time, medical providers and their patients can get DNA formula on demand. For some-more information, greatfully revisit the website at: http://www.spartanbio.com.
The Spartan heading is a purebred heading of Spartan Bioscience Inc.
i-STAT is a purebred heading of Abbott Point of Care Inc.
1. Roberts JD et al. (2012). Lancet. 379:1705–11.
Article Original Source: Click here for details